Biofarm Overview
- Founded
-
1921
- Status
-
Public
- Employees
-
393
- Stock Symbol
-
BIO
- Share Price
-
$0.14
- (As of Tuesday Closing)
Biofarm General Information
Description
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
BSE
Primary Office
- Strase Logofătul Tăutu nr. 99
- Sector 3
- Bucharest, 031212
- Romania
+40 021 000 0000
Biofarm Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.14 | $0.14 | $0.11 - $0.19 | $140M | 985M | 34.2K | $0.02 |
Biofarm Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 88,414 | 159,845 | 86,274 | 62,632 |
| Revenue | 58,918 | 57,398 | 50,939 | 46,028 |
| EBITDA | 21,021 | 19,688 | 17,604 | 16,257 |
| Net Income | 15,600 | 14,492 | 12,772 | 11,990 |
| Total Assets | 91,019 | 95,640 | 94,015 | 81,061 |
| Total Debt | 129 | 148 | 157 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Biofarm Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biofarm Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Catalin Vicol | Board Member & General Manager | ||
| Laura Boer | Chief Accounting Officer | ||
| Liviu Visan | Administrative Manager |
Biofarm Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 0000000000 | Biofarm | Chairman & Board Member | 000 0000 |
| 0000000 00000 | Biofarm | Board Member & General Manager | 000 0000 |
| 0000000-000000 000 | Biofarm | Board Member | 000 0000 |
| 000000 00000 | Biofarm | Board Member | 000 0000 |
Biofarm Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Biofarm Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biofarm ESG
Risk Overview
Risk Rating
Updated November, 10, 2022
32.78 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.0
Percentile
Pharmaceuticals
Subindustry
00 of 473
Rank
00.00
Percentile
